Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study

M. Chaparro, A. Verreth, T. Lobaton, E. Gravito-Soares, M. Julsgaard, E. Savarino, F. Magro, I. Avni Biron, P. Lopez-Serrano, M. J. Casanova, M. Gompertz, S. Vitor, M. Arroyo, D. Pugliese, Y. Zabana, R. Vicente, M. Aguas, A. Bar Gil Shitrit, A. Gutierrez, G. A. DohertyL. Fernandez-Salazar, J. Martínez Cadilla, J. M. Huguet, A. O’Toole, E. Stasi, N. Manceñido Marcos, A. Villoria, K. Karmiris, J. F. Rahier, C. Rodriguez, M. Diz-Lois Palomares, G. Fiorino, J. M. Benitez, M. Principi, T. Naftali, C. Taxonera, G. Mantzaris, L. Sebkova, B. Iade, D. Lissner, I. Ferrer Bradley, A. Lopez San Roman, I. Marin-Jimenez, O. Merino, M. Sierra, M. Van Domselaar, F. Caprioli, I. Guerra, P. Peixe, M. Piqueras

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study'. Together they form a unique fingerprint.

Medicine & Life Sciences